Recently, anti-vascular endothelial growth factor (VEGF) agents have been tried in the management of diabetic retinopathy and proliferative vascular disorders such as Coats' disease with modest success.[3–5] We report our experience in the management of recalcitrant and severe stages of Coats' disease with anti-VEGF agents. The gene discussed is VEGFA; the disease is diabetic retinopathy.